02.11.2018 • News

DCAT Announces New Board of Directors

Paolo Magri, senior vice president, business development at Advitech, has been...
Paolo Magri, senior vice president, business development at Advitech, has been elected president of the Drug, Chemical & Associated Technologies Association (DCAT).

Paolo Magri, senior vice president, business development at Advitech, has been elected president of the Drug, Chemical & Associated Technologies Association (DCAT). Also elected to serve as officers of DCAT are: Stephan Kutzer, president and CEO of Alcami, as first vice president; Sean Diver, director, business development, early intermediates at Lonza, as second vice president; and Kerri McCullough Wood, senior vice president and head of commercial, TAPI, Teva. All will serve one-year terms, effective Nov. 1, 2018.

In addition, the following individuals have been newly elected or will continue to serve one-year terms on the board.

Directors:

Elodie Cramer, associate director, Global Procurement, Biogen

Charles Davies, associate vice president, Global Sourcing & Procurement, Merck & Co.

Sally Macaluso, Vice president, Johnson & Johnson Marketing and Business Services Procurement, Johnson & Johnson

Steve Poland, global director, 3rd Party FDF Technical Support, Mylan

Sami Yusuf, vice president, Corporate Development, Upsher-Smith

Past Presidents:

Immediate Past President: Joe Sutton, Global Director, Sourcing, Eli Lilly

2nd Immediate Past President: Milton Boyer, CEO, SCA Pharmaceuticals

Company

Logo:

DCAT - Drug, Chemical & Associated Technologies Association

One Union St., Suite 208
Robbinsville
US

Company contact







Virtual Event

High Performance Food Production
Perfection Starts in the Tank

High Performance Food Production

On Demand | Optimize your food production with smarter mixing—join the Ystral seminar to discover 20 real-world applications that cut processing times, reduce costs, and boost product quality.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read